Dynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Stein, Andrew ^a   Wang, Wenping ^b   Carter, Alison A ^b   Chiparus, Ovidiu ^b   Hollaender, Norbert ^b   Kim, Hyewon ^c   Motzer, Robert J ^d   Sarr, Celine ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Efficacy; Kidney; Oncology; Pharmacodynamics; Therapeutics

Indexed keywords

EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PLACEBO;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; HUMAN; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; METASTASIS POTENTIAL; MOLECULAR DYNAMICS; ONCOLOGICAL PARAMETERS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION RESEARCH; PROCESS DEVELOPMENT; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUM OF THE LONGEST TUMOR DIAMETER; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MODEL; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PLACEBOS; RETROSPECTIVE STUDIES; SIROLIMUS;

EID: 84868682369     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-311     Document Type: Article

References (26)

1. Garnock-Jones KP, Keating GM. Everolimus: in advanced renal cell carcinoma. Drugs 2009, 69:2115-2124. 10.2165/11203770-000000000-00000, 19791829.
2. Yuan R, Kay A, Berg WJ, Lebwohl D. Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009, 2:45-54. 10.1186/1756-8722-2-45, 2775749, 19860903.
3. Pinto MA, Redondo SA, Espinosa AE, Zamora AP, Castelo FB, Gonzalez BM. mTOR pathway inhibition in renal cell carcinoma. Urol Oncol 2010,
4. Youssif TA, Fahmy MA, Koumakpayi IH, Ayala F, Al Marzooqi S, Chen G, et al. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases. Cancer 2011, 117:290-300. 10.1002/cncr.25402, 20830770.
5. Romaschin AD, Youssef Y, Chow TF, Siu KW, DeSouza LV, Honey RJ, et al. Exploring the pathogenesis of renal cell carcinoma: pathway and bioinformatics analysis of dysregulated genes and proteins. Biol Chem 2009, 390:125-135.
6. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430. 10.1038/nature04869, 16724053.
7. O'Reilly T, McSheehy PM. Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals. Transl Oncol 2010, 3:65-79. 2847314, 20360931.
8. O'Donnell A, Faivre S, Burris HA, Rea D, Papadimitrakopoulou V, Shand N, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008, 26:1588-1595. 10.1200/JCO.2007.14.0988, 18332470.
9. Tabernero J, Rojo F, Calvo E, Burris H, Judson I, Hazell K, et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610. 10.1200/JCO.2007.14.5482, 18332469.
10. Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004, 64:252-261. 10.1158/0008-5472.CAN-3554-2, 14729632.
11. Tanaka C, O'Reilly T, Kovarik JM, Shand N, Hazell K, Judson I, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008, 26:1596-1602.
12. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer 2009, 115:2438-2446. 10.1002/cncr.24280, 19306412.
13. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008, 372:449-456. 10.1016/S0140-6736(08)61039-9, 18653228.
14. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010, 116:4256-4265. 10.1002/cncr.25219, 20549832.
15. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216. 10.1093/jnci/92.3.205, 10655437.
16. Oudard S, Thiam R, Fournier LS, Medioni J, Lamuraglia M, Scotte F, et al. Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: Analysis of response and progression-free survival in the RECORD-1 study. Eur J Cancer 2012,
17. Lavin PT. An alternative model for the evaluation of anti tumor activity. Cancer Clin Trials 1981, 4:451-457.
18. Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemother Pharmacol 2010, 66:357-371. 10.1007/s00280-009-1170-y, 19967539.
19. Tham LS, Wang L, Soo RA, Lee SC, Lee HS, Yong WP, et al. A pharmacodynamic model for the time course of tumor shrinkage by Gemcitabine + Carboplatin in non-small cell lung cancer patients. Clin Cancer Res 2008, 174:4213-4218.
20. Wang W, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, et al. Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 2009, 86:167-174. 10.1038/clpt.2009.64, 19440187.
21. Claret L, Girard P, Hoff PM, Van Cutsem E, Zuideveld KP, Jorga K, et al. Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics. J Clin Oncol 2009, 27:4103-4108. 10.1200/JCO.2008.21.0807, 19636014.
22. Stein A, Carter A, Hollaender N, Motzer R, Sarr C. Quantifying the effect of everolimus on both tumor growth and new metastases in metastatic renal cell carcinoma: a dynamic tumor model of the RECORD-1 phase 3 trial. J Clin Oncol 2011, 29(suppl; abstr 4602).
23. Fleming TR, Lin DY. Survival analysis in clinical trials: past developments and future directions. Biometrics 2000, 56:971-983. 10.1111/j.0006-341X.2000.0971.x, 11129494.
24. Mu S, Wang J, Li J, Visich J, Schaedeli-Stark F, Valente N, et al. Modeling longitudinal tumor metrics in NHL patients treated with rituximab: application of the Norton-Simon hypothesis incorporating gompertzian growth 2009, Mashantucket, CT: American Conference of Pharmacometrics (ACOP).
25. Porta C, Ostanto S, Ravaud A, Climent MA, Vaishampayan U, White DA, et al. Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma. Eur J Cancer 2011, 47:1287-1298. 10.1016/j.ejca.2011.02.014, 21481584.
26. Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS Pharm Sci 2002, 4:E27.